Dabigatran and other novel oral anticoagulants are effective and safe for reducing thromboembolic risk in the setting non-valvular AF. However, it remains unclear whether these newer anticoagulants are as effective as warfarin for reducing thromboembolic complications among patients with mechanical heart valves. As oral anticoagulation is a mainstay of therapy in patients with mechanical valves, […]